

dalfampridine (AMPYRA)

Diagnosis Considered for Coverage:

- Improved walking in patients with multiple sclerosis

Commercial Coverage Criteria:

For diagnosis of maintaining walk speed in patients with multiple sclerosis:

Initial Request:

- Being prescribed by or in consultation with a neurologist or MS specialist, **and**
- Documentation that patient has completed a baseline timed 25-foot walking test, **and**
- Dose does not exceed 20 mg per day.

Reauthorization

- Patient's walking speed has improved or been maintained with treatment, **and**
- Dose does not exceed 20 mg per day.

Coverage Duration:

Initial: 3 months

Reauthorization: one year

Effective Date: 11/30/2022